Search Results

Tofacitinib 10 mg  | 99.74%

TargetMol

Tofacitinib is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis.

More Information Supplier Page

Tofacitinib 100 mg  | 99.74%

TargetMol

Tofacitinib is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis.

More Information Supplier Page

Go 6983 5 mg  | 98.84%

TargetMol

Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

More Information Supplier Page

Go 6983 50 mg  | 98.84%

TargetMol

Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

More Information Supplier Page

Go 6983 25 mg  | 98.84%

TargetMol

Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

More Information Supplier Page

Go 6983 10 mg  | 98.84%

TargetMol

Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

More Information Supplier Page

(E/Z)-BIX02188 10 mg  | 99.21%

TargetMol

BIX02188 is a specific MEK5 inhibitor (IC50: 4.3 nM), also inhibits ERK5 catalytic activity (IC50: 810 nM), and does not inhibit closely related kinases MEK1/2, JNK2, and ERK2.

More Information Supplier Page

(E/Z)-BIX02188 25 mg  | 99.21%

TargetMol

BIX02188 is a specific MEK5 inhibitor (IC50: 4.3 nM), also inhibits ERK5 catalytic activity (IC50: 810 nM), and does not inhibit closely related kinases MEK1/2, JNK2, and ERK2.

More Information Supplier Page